OBJECTIVES:  This study describes trends in Average Wholesale Prices (AWP) at market entry of Tuberculosis (TB) drugs and vaccines approved by the FDA and marketed in the US in the period 1973 -2016. METHODS: The AWP per unit at market entry and market entry dates were collected from the Redbook (Truven Health Analytics Inc.) for TB drugs approved by the FDA. The AWP was collected from the effective date to January 2017, and price at market entry was converted to 2016 USD using AWP per unit/CPI adjusted for November 2016. RESULTS: Twenty-six TB drugs and vaccines approved by the FDA were included in the analysis, seven of which were approved from 1973-1989, eight from 1990-1999, and eleven from 2000-2016. The market entry CPI-adjusted AWP per DDD from 1973-1989 was $207.20 for the first TB drug (Hydrocortisone), from 1990-1998 it was $147.73 for Bacillus of Calmette and Guerin (BCG vaccine) and, from 2000-2016 it was $3.42 for Hydrocortisone. The highest TB drug prices recorded from 1973-1989 was $58.65 for Rifampin (intravenous), $3.29 for Hydrocortisone (topical), $1.61 for a combination of Isoniazid and Rifampin (oral), $1.3 for Prednisolone Acetate (ophthalmic), $2.08 for Tuberculin (intradermal) and, $36.54 for Methylprednisolone sodium succinate (intravenous or intramuscular). From 1990-1998 these prices were $147.73 for BCG vaccine live (urinary bladder), $5.15 for Hydrocortisone (topical), $3.74 for Aminosalicylic acid (oral), $8.58 for Ciprofloxacin hydrochloride (ophthalmic), and $5.51 for Streptomycin sulfate (intramuscular). For the period 2000-2016 the prices were $5408.41 for Gatifloxacin (ophthalmic), $168.59 for BCG vaccine, live (intradermal), $175.27 for Capreomycin (injection), $214.6 for Rifampin (intravenous) and $191.79 for Bedaquiline fumarate (oral) among others. CONCLUSIONS: The FDA approved numerous drugs for treatment of TB during the study period. The study found an increase in the prices of TB drugs at market entry during the same period.